TaiMed Biologics (4147) Stock Overview
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
4147 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
TaiMed Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$86.10 |
| 52 Week High | NT$108.50 |
| 52 Week Low | NT$65.90 |
| Beta | 0.018 |
| 1 Month Change | -9.94% |
| 3 Month Change | 13.44% |
| 1 Year Change | -1.15% |
| 3 Year Change | 45.44% |
| 5 Year Change | -0.58% |
| Change since IPO | 313.94% |
Recent News & Updates
Recent updates
TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook
Apr 20
TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%
Mar 16TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.
Feb 09Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven
Jan 05
TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?
Dec 01Shareholder Returns
| 4147 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 1.9% | 1.7% | 2.6% |
| 1Y | -1.1% | -18.0% | 0.7% |
Return vs Industry: 4147 exceeded the TW Biotechs industry which returned -18% over the past year.
Return vs Market: 4147 underperformed the TW Market which returned 0.7% over the past year.
Price Volatility
| 4147 volatility | |
|---|---|
| 4147 Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 4147 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4147's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Jimmy Chang | www.taimedbiologics.com |
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates, for cancer treatment.
TaiMed Biologics Inc. Fundamentals Summary
| 4147 fundamental statistics | |
|---|---|
| Market cap | NT$23.84b |
| Earnings (TTM) | -NT$211.59m |
| Revenue (TTM) | NT$607.46m |
Is 4147 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4147 income statement (TTM) | |
|---|---|
| Revenue | NT$607.46m |
| Cost of Revenue | NT$373.16m |
| Gross Profit | NT$234.30m |
| Other Expenses | NT$445.89m |
| Earnings | -NT$211.59m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 38.57% |
| Net Profit Margin | -34.83% |
| Debt/Equity Ratio | 12.2% |
How did 4147 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/21 11:26 |
| End of Day Share Price | 2025/07/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TaiMed Biologics Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Chu Wang | Citigroup Inc |
| null null | Credit Suisse |